<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573468</url>
  </required_header>
  <id_info>
    <org_study_id>TOG301</org_study_id>
    <secondary_id>2010-022164-12</secondary_id>
    <nct_id>NCT01573468</nct_id>
  </id_info>
  <brief_title>Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer</brief_title>
  <acronym>TESEGAST</acronym>
  <official_title>A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to evaluate the efficacy and safety of capecitabine in
      combination with tesetaxel versus capecitabine in combination with placebo as second-line
      treatment for patients with gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>When at least 508 events of death have occurred, which is estimated will occur 12 months after the date of randomization of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Estimated will be assessed 12 months after the date of randomization of the last patient</time_frame>
    <description>The percentages of patients with complete or partial response of any duration or stable disease lasting at least 6 weeks from the date of randomization (revised RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Estimated will be assessed 12 months after the date of randomization of the last patient</time_frame>
    <description>Calculated from the date of randomization to the date when disease progression is first documented or when the patient dies within 60 days of the last lesion assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in patients with measurable disease</measure>
    <time_frame>Estimated will be assessed 12 months after the date of randomization of the last patient</time_frame>
    <description>The percentages of patients with complete or partial response (revised RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 30 days after the last dose of study medication</time_frame>
    <description>The percentages of patients who experience adverse events by specific adverse event term</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>Capecitabine-tesetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine-placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle</description>
    <arm_group_label>Capecitabine-tesetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally once on Day 1 of each cycle</description>
    <arm_group_label>Capecitabine-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle</description>
    <arm_group_label>Capecitabine-tesetaxel</arm_group_label>
    <arm_group_label>Capecitabine-placebo</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          1. Histologically or cytologically confirmed gastric adenocarcinoma, including gastric or
             gastroesophageal-junction adenocarcinoma (Histologically confirmed adenocarcinoma of
             the lower esophagus acceptable with radiographic or endoscopic documentation of
             gastroesophageal-junction or proximal-stomach involvement.)

          2. Measurable disease (revised RECIST) based on computed tomography, or nonmeasurable
             disease

          3. ECOG performance status 0 or 1

          4. Treatment with only 1 prior regimen (as first-line therapy) that must have included a
             fluoropyrimidine and a platinum-containing agent (Prior adjuvant or neo-adjuvant
             chemotherapy acceptable provided 6 months elapsed between the end of this therapy and
             the start of first-line therapy.)

          5. Disease progression after the start of the 1 prior regimen based on computed
             tomography

          6. Adequate bone marrow, hepatic, and renal function

          7. Ability to swallow an oral solid-dosage form of medication

        Key exclusion criteria:

          1. Squamous cell gastric carcinoma

          2. Bone-only metastatic disease

          3. History or presence of brain metastasis or leptomeningeal disease

          4. Operable gastric or gastroesophageal-junction cancer

          5. HER2-positive disease if the patient has not previously been treated with an anti-HER2
             agent

          6. Uncontrolled diarrhea, nausea, or vomiting

          7. Known malabsorptive disorder

          8. Significant medical disease other than gastric cancer

          9. Presence of neuropathy &gt; Grade 1 (NCI Common Toxicity Criteria)

         10. Prior treatment (including adjuvant therapy) with a taxane or other tubulin-targeted
             agent (indibulin, eribulin, etc.)

         11. Prior radiation therapy to more than 25% of the bone marrow

         12. Need to continue any regularly-taken medication that is a potent inhibitor or inducer
             of the CYP3A pathway

         13. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaffer Ajani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas MD Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mansoor Ahmad, MD, PhD</last_name>
    <phone>908 286-3113</phone>
    <email>medinfo@genta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaffer Ajani, MD</last_name>
      <phone>713-745-3917</phone>
    </contact>
    <investigator>
      <last_name>Jaffer Ajani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran, PD Dr. med</last_name>
      <phone>+49 (0) 69 7601 4420</phone>
    </contact>
    <investigator>
      <last_name>Salah-Eddin Al-Batran, PD Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Jui Yen, MD</last_name>
      <phone>+886 6 2353535 4620</phone>
    </contact>
    <investigator>
      <last_name>Chia-Jui Yen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

